Biogen has inked neurology disease deals with privately-owned companies C4 Therapeutics and Skyhawk Therapeutics. The market seems to approve, with the biotech's stock closing up nearly 4% on Friday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,